These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 27570065)

  • 1. The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines.
    Kotantaki P; Mosialos G
    Cell Biochem Funct; 2016 Oct; 34(7):465-468. PubMed ID: 27570065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down-regulation of CYLD as a trigger for NF-κB activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells.
    Urbanik T; Köhler BC; Boger RJ; Wörns MA; Heeger S; Otto G; Hövelmeyer N; Galle PR; Schuchmann M; Waisman A; Schulze-Bergkamen H
    Int J Oncol; 2011 Jan; 38(1):121-31. PubMed ID: 21109933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel histone deacetylase inhibitor MPT0G009 induces cell apoptosis and synergistic anticancer activity with tumor necrosis factor-related apoptosis-inducing ligand against human hepatocellular carcinoma.
    Chen MC; Huang HH; Lai CY; Lin YJ; Liou JP; Lai MJ; Li YH; Teng CM; Yang CR
    Oncotarget; 2016 Jan; 7(1):402-17. PubMed ID: 26587975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma.
    Srinivas C; Swathi V; Priyanka C; Anjana Devi T; Subba Reddy BV; Janaki Ramaiah M; Bhadra U; Bhadra MP
    Apoptosis; 2016 Nov; 21(11):1249-1264. PubMed ID: 27502208
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic and epigenetic inactivation of T-cadherin in human hepatocellular carcinoma cells.
    Chan DW; Lee JM; Chan PC; Ng IO
    Int J Cancer; 2008 Sep; 123(5):1043-52. PubMed ID: 18553387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma.
    Pannem RR; Dorn C; Ahlqvist K; Bosserhoff AK; Hellerbrand C; Massoumi R
    Carcinogenesis; 2014 Feb; 35(2):461-8. PubMed ID: 24104553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histone deacetylase inhibitors promote ATP2A3 gene expression in hepatocellular carcinoma cells: p300 as a transcriptional regulator.
    Hernández-Oliveras A; Izquierdo-Torres E; Meneses-Morales I; Rodríguez G; Zarain-Herzberg Á; Santiago-García J
    Int J Biochem Cell Biol; 2019 Aug; 113():8-16. PubMed ID: 31146004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer.
    Chen CQ; Chen CS; Chen JJ; Zhou LP; Xu HL; Jin WW; Wu JB; Gao SM
    Mol Cell Biochem; 2013 Nov; 383(1-2):137-48. PubMed ID: 23867991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDAC inhibitor treatment of hepatoma cells induces both TRAIL-independent apoptosis and restoration of sensitivity to TRAIL.
    Pathil A; Armeanu S; Venturelli S; Mascagni P; Weiss TS; Gregor M; Lauer UM; Bitzer M
    Hepatology; 2006 Mar; 43(3):425-34. PubMed ID: 16583461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cell growth inhibition and gene expression induced by the histone deacetylase inhibitor, trichostatin A, on human hepatoma cells.
    Chiba T; Yokosuka O; Fukai K; Kojima H; Tada M; Arai M; Imazeki F; Saisho H
    Oncology; 2004; 66(6):481-91. PubMed ID: 15452378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tissue factor pathway inhibitor-2 as a frequently silenced tumor suppressor gene in hepatocellular carcinoma.
    Wong CM; Ng YL; Lee JM; Wong CC; Cheung OF; Chan CY; Tung EK; Ching YP; Ng IO
    Hepatology; 2007 May; 45(5):1129-38. PubMed ID: 17464989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The interferon-alpha responsive gene TMEM7 suppresses cell proliferation and is downregulated in human hepatocellular carcinoma.
    Zhou X; Popescu NC; Klein G; Imreh S
    Cancer Genet Cytogenet; 2007 Aug; 177(1):6-15. PubMed ID: 17693185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pan-deacetylase inhibitor panobinostat suppresses the expression of oncogenic miRNAs in hepatocellular carcinoma cell lines.
    Henrici A; Montalbano R; Neureiter D; Krause M; Stiewe T; Slater EP; Quint K; Ocker M; Di Fazio P
    Mol Carcinog; 2015 Aug; 54(8):585-97. PubMed ID: 24375802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear expression of the deubiquitinase CYLD is associated with improved survival in human hepatocellular carcinoma.
    Welte S; Urbanik T; Elßner C; Kautz N; Koehler BC; Waldburger N; Bermejo JL; Pinna F; Weiss KH; Schemmer P; Jaeger D; Longerich T; Breuhahn K; Schulze-Bergkamen H
    PLoS One; 2014; 9(10):e110591. PubMed ID: 25329885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines.
    Zopf S; Ocker M; Neureiter D; Alinger B; Gahr S; Neurath MF; Di Fazio P
    BMC Cancer; 2012 Sep; 12():386. PubMed ID: 22943463
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptosis on hepatoma cells but not on primary hepatocytes by histone deacetylase inhibitors valproate and ITF2357.
    Armeanu S; Pathil A; Venturelli S; Mascagni P; Weiss TS; Göttlicher M; Gregor M; Lauer UM; Bitzer M
    J Hepatol; 2005 Feb; 42(2):210-7. PubMed ID: 15664246
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of mPTP-dependent mitochondrial apoptosis pathway by a novel pan HDAC inhibitor resminostat in hepatocellular carcinoma cells.
    Fu M; Shi W; Li Z; Liu H
    Biochem Biophys Res Commun; 2016 Sep; 477(4):527-533. PubMed ID: 27144317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The preclinical activity of the histone deacetylase inhibitor PXD101 (belinostat) in hepatocellular carcinoma cell lines.
    Ma BB; Sung F; Tao Q; Poon FF; Lui VW; Yeo W; Chan SL; Chan AT
    Invest New Drugs; 2010 Apr; 28(2):107-14. PubMed ID: 19172229
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma.
    Venturelli S; Armeanu S; Pathil A; Hsieh CJ; Weiss TS; Vonthein R; Wehrmann M; Gregor M; Lauer UM; Bitzer M
    Cancer; 2007 May; 109(10):2132-41. PubMed ID: 17407132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene expression associated with the decrease in malignant phenotype of human liver cancer cells following stimulation with a histone deacetylase inhibitor.
    Wakabayashi K; Saito H; Kaneko F; Nakamoto N; Tada S; Hibi T
    Int J Oncol; 2005 Jan; 26(1):233-9. PubMed ID: 15586245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.